| Aug 24 |
Investors in Johnson & Johnson (NYSE:JNJ) have seen notable returns of 46% over the past five years
|
| Aug 23 |
J&J Takes Aim at Hospital Drug-Discount Program
|
| Aug 23 |
Johnson & Johnson continues gains for eight straight sessions
|
| Aug 23 |
J&J reportedly seeking additional support for talc bankruptcy plan
|
| Aug 23 |
Update: Market Chatter: Johnson & Johnson Unveils New Strategy on Hospital Drug-Discount Program
|
| Aug 23 |
J&J faces backlash from hospitals after revised drug-discount program: WSJ
|
| Aug 23 |
J&J in talks with holdouts to $6.5 billion talc settlement
|
| Aug 23 |
Johnson & Johnson: The Dividend King Is Back
|
| Aug 23 |
Dividend Roundup: Johnson & Johnson, Hyatt, Northrop Grumman, Altria Group, and more
|
| Aug 22 |
Johnson & Johnson: Don't Bet Against Double Compounding
|
